EvolutionaryScale lands $142 mln to advance AI in biology
By Anna Tong and Krystal Hu
June 25 -EvolutionaryScale, an artificial intelligence startup focused on biology, said Tuesday it had raised $142 million in seed funding, led by Nat Friedman, Daniel Gross and Lux Capital.
Amazon AMZN.O Web Services (AWS) and the venture capital arm of NVIDIA NVDA.O also participated in the fund raising.
Calling it a "ChatGPT moment for biology," Lux Capital co-founder and managing partner Josh Wolfe told Reuters the company has developed the first large language model for creating novel proteins and other biological systems.
EvolutionaryScale envisions its AI being utilized for a wide range of applications, from accelerating drug discovery to engineering microbes capable of breaking down plastic in the environment, the company's chief scientist Alex Rives told Reuters.
Using AI to engineer new biological systems is currently an area of intense interest.
Microsoft MSFT.O-backed OpenAI announced a partnership with French drugmaker Sanofi SASY.PA in May to boost its drug development projects using AI.
At the same time, experts have also raised alarm bells about generative AI's potential to help create bioweapons, through aiding the development of harmful pathogens or toxins.
EvolutionaryScale's funding will be used to train its next generation of AI models as well as build out a team to partner with the biotech industry, Rives said.
The company is releasing models named ESM3. The smaller ESM3 model is being open sourced for non-commercial research, and AWS and NVIDIA will make the models available commercially, including its largest ESM3 model, the company said.
The company said it leveraged ESM3 to engineer a novel fluorescent protein that diverged from the evolutionary path of naturally occurring fluorescent proteins, which would have taken nature about 500 million years to evolve.
Reporting by Anna Tong in San Francisco; Editing by Lincoln Feast.
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
